TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28619696

Group type: EXPERIMENTAL
Intervention: Multimodal analgesia (mainly antipyretic analgesics, nonsteroidal anti-inflammatory drugs, opioids)
Number of subjects: 2922

Group type: EXPERIMENTAL
Intervention: Epidurals in abdominal surgery
Number of subjects: 2922

Group type: EXPERIMENTAL
Intervention: Acute opioid treatments
Number of subjects: 2922

Group type: EXPERIMENTAL
Intervention: Regional analgesia
Number of subjects: 2922

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 2922

Group type: EXPERIMENTAL
Intervention: Chronic pain (>7) and/or chronic opioid consumption before surgery
Number of subjects: 2922

Group type: EXPERIMENTAL
Intervention: Tibia/fibula and foot surgeries (ORT), gastric, small intestine, and anterior abdominal wall procedures (GEN)
Number of subjects: 2922

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (intravenous morphine)
Number of subjects: 2922

Group type: EXPERIMENTAL
Intervention: Pain assessment and information
Number of subjects: 2922
Study: 25759961

Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation (10 mg Zn/day) and venous zinc administration (0.06537 mg Zn/kg of body weight) in the experimental group.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group using 10% sorbitol.
Number of subjects: 40
Study: 23545928

Group type: EXPERIMENTAL
Intervention: Hydroquinone-free skin brightening product
Number of subjects: 18

Group type: COMPARATOR
Intervention: 4% HQ cream
Number of subjects: 18
Study: 21042875

Group type: EXPERIMENTAL
Intervention: Krill oil (N = 36; 3.0 g/day, EPA + DHA = 543 mg)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Fish oil (N = 40; 1.8 g/day, EPA + DHA = 864 mg)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (N = 37)
Number of subjects: 113
Study: 18719059

Group type: COMPARATOR
Intervention: Aminoguanidine (iNOS inhibitor)
Number of subjects: 0
Study: 17370486

Group type: EXPERIMENTAL
Intervention: Acupuncture at Zhongwan (CV 12) with deep needling
Number of subjects: 276

Group type: COMPARATOR
Intervention: Climetidine (control group)
Number of subjects: 276
Study: 15307342

Group type: EXPERIMENTAL
Intervention: Computer-based training
Number of subjects: 1294

Group type: COMPARATOR
Intervention: Instructor-led training
Number of subjects: 1294
Study: 11266238

Group type: EXPERIMENTAL
Intervention: Adrenaline-Pirquet test (aP)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Mantoux test with PPD 2 TU (M2)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Mantoux test with PPD 5 TU (M5)
Number of subjects: 585

Group type: COMPARATOR
Intervention: PPD 2 TU-Rhoditest (Rh)
Number of subjects: 585
Study: 9354206

Group type: EXPERIMENTAL
Intervention: Oral benzocaine 0.75% solution (n = 14)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Benzocaine-free solvent (placebo, n = 12)
Number of subjects: 26
Study: 7872981

Group type: EXPERIMENTAL
Intervention: Exercise + diet (E) group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 16
Study: 3046105

Group type: COMPARATOR
Intervention: Phenylpropanolamine (PPA) alone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Estriol alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Estriol and PPA in combination
Number of subjects: 36
Study: 29250706

Group type: EXPERIMENTAL
Intervention: Acidic saline (AS, pH 5)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Neutral saline (NS, pH 7.4)
Number of subjects: 28
Study: 27412192

Group type: EXPERIMENTAL
Intervention: Remote ischemic per-conditioning (four cycles of electronic tourniquet inflation and deflation for 5 minutes each)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Remote ischemic per-conditioning
Number of subjects: 200
Study: 24103188

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis ssp. lactis Bf-6 (LMG 24384) yogurt
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 68
Study: 22177808

Group type: EXPERIMENTAL
Intervention: Grafted sites with an anorganic xenograft plus a membrane
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nongrafted sites
Number of subjects: 28
Study: 20831528

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 5 mg/kg/h for 6 hours for 6 successive days
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 37
Study: 18711190

Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interleukin-2 (IL-2)
Number of subjects: 0
Study: 15867559

Group type: EXPERIMENTAL
Intervention: C-labeled nandrolone (25 mg dose, followed by a second identical dose 24 hours later)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 12409588

Group type: EXPERIMENTAL
Intervention: Low-dose spiral computed tomography (CT)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 304
Study: 9861520

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg daily
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 69
Study: 8583024

Group type: EXPERIMENTAL
Intervention: Visual methods for assessing vital plaque
Number of subjects: 12

Group type: COMPARATOR
Intervention: Image capture system linked to a computerised image programme
Number of subjects: 12
Study: 2224950

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate 20 micrograms
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate 40 micrograms
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (during open-label period)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 6965330

Group type: EXPERIMENTAL
Intervention: Selective distal splenorenal shunt
Number of subjects: 0

Group type: COMPARATOR
Intervention: End‐to‐side portacaval shunt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective distal splenorenal shunt and End‐to‐side portacaval shunt
Number of subjects: 0
Study: 31634418

Group type: EXPERIMENTAL
Intervention: Genetic Risk Score (GRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pruning and Thresholding (P + T)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linkage Disequilibrium Prediction (LDpred)
Number of subjects: 0
Study: 30703523

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (individual phone counseling and social marketing campaign)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 352
Study: 28121172

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation consisting of 12 weeks of physical exercise training and monthly psycho-educational consultations
Number of subjects: 147

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 147
Study: 25811287

Group type: EXPERIMENTAL
Intervention: 1% lignocaine
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: 2% lignocaine
Number of subjects: 500
Study: 23890493

Group type: EXPERIMENTAL
Intervention: Volar locking plates (VLP)
Number of subjects: 111

Group type: COMPARATOR
Intervention: External fixation (EF)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Volar locking plates (VLP) and External fixation (EF)
Number of subjects: 111
Study: 21980810

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 19671410

Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu (XFZY) Capsule
Number of subjects: 90

Group type: COMPARATOR
Intervention: Shengmai (SM) Capsule
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 17077230

Group type: EXPERIMENTAL
Intervention: Increased access to emergency contraceptive pills (two packages dispensed in advance with unlimited resupply at no charge)
Number of subjects: 1490

Group type: COMPARATOR
Intervention: Standard access to emergency contraceptive pills (pills dispensed when needed at usual charges)
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Increased access to emergency contraceptive pills
Number of subjects: 1490

Group type: COMPARATOR
Intervention: Standard access to emergency contraceptive pills
Number of subjects: 1490
Study: 15582766

Group type: EXPERIMENTAL
Intervention: Training by lay person
Number of subjects: 38

Group type: COMPARATOR
Intervention: Training by health care professional
Number of subjects: 38
Study: 11531217

Group type: EXPERIMENTAL
Intervention: Choline-supplemented TPN (2 g choline chloride added)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Usual TPN (placebo)
Number of subjects: 15
Study: 9989314

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral stress management program (CBSM)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 8091249

Group type: EXPERIMENTAL
Intervention: Teicoplanin i.v. once a day
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Teicoplanin i.m. once a day
Number of subjects: 96

Group type: COMPARATOR
Intervention: Cefazolin i.v. every 8 hours
Number of subjects: 96
Study: 3069751

Group type: EXPERIMENTAL
Intervention: Two tablets of 100 mg ibopamine (SIMES formulations)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Two tablets of 100 mg ibopamine (UK formulation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: One tablet of 200 mg ibopamine (US-Tiltab formulation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: One tablet of 200 mg ibopamine (US-Tiltab formulation) on a 4th occasion
Number of subjects: 30
Study: 31911667

Group type: EXPERIMENTAL
Intervention: Denosumab (DMAb)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bisphosphonates or calcium and vitamin D
Number of subjects: 0
Study: 29465052

Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscope (FOB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Direct laryngoscope (DLS)
Number of subjects: 80
Study: 27353617

Group type: EXPERIMENTAL
Intervention: Pregnancy surveillance performance (referrals of pregnant women)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Nutrition and hygiene education performance (lesson delivery)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Job satisfaction and motivation measures
Number of subjects: 342
Study: 24584382

Group type: EXPERIMENTAL
Intervention: Trimebutine 100mg twice daily
Number of subjects: 140

Group type: COMPARATOR
Intervention: Mebeverine 135mg twice daily
Number of subjects: 140
Study: 23228348

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Infliximab (IFX)
Number of subjects: 37
Study: 21422302

Group type: EXPERIMENTAL
Intervention: lidocaine plus bupivacaine plus clonidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: lidocaine plus bupivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 120
Study: 18450862

Group type: EXPERIMENTAL
Intervention: European Bladder Dysfunction Study treatment
Number of subjects: 202
Study: 16181604

Group type: EXPERIMENTAL
Intervention: Matte objects with illumination from different directions
Number of subjects: 6

Group type: COMPARATOR
Intervention: Glossy objects with illumination from different directions
Number of subjects: 6
Study: 15071263

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional hospital admission strategy
Number of subjects: 18
Study: 11068971

Group type: EXPERIMENTAL
Intervention: Multidimensional treatment foster care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Services-as-usual group care
Number of subjects: 0
Study: 8718542

Group type: EXPERIMENTAL
Intervention: Estriol (E3) 2 mg/day + Calcium lactate (Ca) 2 g/day (Group-E3 + Ca)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Calcium lactate (Ca) 2 g/day (Group-Ca)
Number of subjects: 25
Study: 1400926

Group type: EXPERIMENTAL
Intervention: Sequential combination of oestradiol valerate (2 mg, days 1-28) and levonorgestrel (75 micrograms, days 17-28)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Continuous combination of oestradiol valerate (2 mg, days 1-28) and cyproterone acetate (1 mg, days 1-28)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 2935765

Group type: EXPERIMENTAL
Intervention: 1% etidocaine 5 mL dropped on each fallopian tube before tubal banding
Number of subjects: 51

Group type: COMPARATOR
Intervention: No topical anesthetic agent
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 1% etidocaine 5 mL
Number of subjects: 51
Study: 31567602

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 52
Study: 28404769

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 60
Study: 26216195

Group type: EXPERIMENTAL
Intervention: Whey protein (32.2 g pre- and post-rehabilitation for two weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no whey protein)
Number of subjects: 38
Study: 24531027

Group type: EXPERIMENTAL
Intervention: Tube shunt (350 mm² Baerveldt glaucoma implant)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (0.4 mg/mL for 4 minutes)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Tube shunt
Number of subjects: 212

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 212
Study: 22796902

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich dark chocolate (DC) 20 g containing 500 mg polyphenols
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo DC with negligible polyphenol-content
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich dark chocolate (DC)
Number of subjects: 42
Study: 20028945

Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention for 1 year
Number of subjects: 58
Study: 17901959

Group type: EXPERIMENTAL
Intervention: Coronary calcium scores (CCS) by electron beam computed tomography (Agatston score)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Exercise testing
Number of subjects: 304
Study: 19372312

Group type: EXPERIMENTAL
Intervention: pH-stat blood gas management
Number of subjects: 40

Group type: COMPARATOR
Intervention: alpha-stat blood gas management
Number of subjects: 40
Study: 15022053

Group type: EXPERIMENTAL
Intervention: Breath-hold (BH) phase-contrast technique
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non breath-hold (NBH) cine phase-contrast technique
Number of subjects: 32
Study: 11281233

Group type: EXPERIMENTAL
Intervention: 50 mmol/day salt intake
Number of subjects: 55

Group type: COMPARATOR
Intervention: 150 mmol/day salt intake
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both salt intake levels
Number of subjects: 55
Study: 9388791

Group type: EXPERIMENTAL
Intervention: Computer-generated printed feedback (Experimental group)
Number of subjects: 679

Group type: COMPARATOR
Intervention: Control group (no printed feedback)
Number of subjects: 679
Study: 8187369

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 139
Study: 3250183

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) oral tablets
Number of subjects: 69

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 69
Study: 30658649

Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg every 8 weeks (first three doses every 4 weeks) subcutaneously
Number of subjects: 0
Study: 28254084

Group type: EXPERIMENTAL
Intervention: Daily SMS reminders for medications
Number of subjects: 1198

Group type: COMPARATOR
Intervention: No SMS reminders (Control)
Number of subjects: 1198
Study: 26172565

Group type: EXPERIMENTAL
Intervention: Meal replacement shakes
Number of subjects: 5

Group type: COMPARATOR
Intervention: Behavioral weight management program
Number of subjects: 5
Study: 23664683

Group type: EXPERIMENTAL
Intervention: Placebo analgesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain perception
Number of subjects: 0
Study: 19691834

Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation (2224 mg EPA + 2208 mg DHA for 6 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation
Number of subjects: 14
Study: 17088909

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 753

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: TOP2A amplification
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Cumulative anthracycline dose
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Luminal-like tumours
Number of subjects: 753
Study: 14702491

Group type: EXPERIMENTAL
Intervention: Reminder/recall for influenza vaccination
Number of subjects: 2007

Group type: COMPARATOR
Intervention: Control group (no reminder/recall)
Number of subjects: 2007
Study: 11721215

Group type: EXPERIMENTAL
Intervention: loratadine + Vit. C
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: chlorpheniramine + Vit. C
Number of subjects: 64

Group type: COMPARATOR
Intervention: Vit. C alone
Number of subjects: 64
Study: 9131280

Group type: EXPERIMENTAL
Intervention: Degree of diabetic retinopathy
Number of subjects: 12
Study: 7697674

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.25 mg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Verapamil (0.15 mg/kg)
Number of subjects: 18
Study: 3652753

Group type: EXPERIMENTAL
Intervention: Hydration (drinking one glass of fluid every waking hour after supper and upon waking the next morning)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dry (drinking no fluid after supper and upon waking the next morning)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ad lib (drinking fluid ad libitum)
Number of subjects: 12
Study: 29973190

Group type: EXPERIMENTAL
Intervention: Intervention group (14 sessions of 60 min during an academic year)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 172
Study: 26874511

Group type: EXPERIMENTAL
Intervention: 40 mg of valsartan (low-dose group)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 80 mg of valsartan (regular-dose group)
Number of subjects: 43
Study: 25130503

Group type: EXPERIMENTAL
Intervention: Cluster immunotherapy with high polymerized allergen extract of grass/rye pollen mixture
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 23350192

Group type: EXPERIMENTAL
Intervention: Remaxol
Number of subjects: 0
Study: 19967558

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 18696285

Group type: EXPERIMENTAL
Intervention: Clonidine adhesive patch (1.0mg, 1.5mg, or 2.0mg per week for 4 weeks)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Clonidine adhesive patch
Number of subjects: 437

Group type: COMPARATOR
Intervention: Placebo adhesive patch
Number of subjects: 437
Study: 16159626

Group type: EXPERIMENTAL
Intervention: Rhinovirus illnesses during infancy
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Wheezing during rhinovirus seasons
Number of subjects: 285
Study: 11837055

Group type: EXPERIMENTAL
Intervention: Restricting bending activities in the early morning
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 60
Study: 9613269

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.2 mg.kg‐1
Number of subjects: 60
Study: 8598261

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) at low dosage
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 225
Study: 2750570

Group type: EXPERIMENTAL
Intervention: Description of a fellow student as a smoker
Number of subjects: 0

Group type: COMPARATOR
Intervention: Description of a fellow student without the smoking information
Number of subjects: 0
Study: 1058422

Group type: EXPERIMENTAL
Intervention: Ointment containing estrone alone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ointment of estrone and progesterone
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo base ointment
Number of subjects: 61
Study: 31806426

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 1629
Study: 30390361

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 2964

Group type: EXPERIMENTAL
Intervention: Weight change among high-weight participants
Number of subjects: 2964

Group type: EXPERIMENTAL
Intervention: Weight loss >5%
Number of subjects: 2964

Group type: EXPERIMENTAL
Intervention: Weight loss 0-<=5%
Number of subjects: 2964

Group type: COMPARATOR
Intervention: Weight gain 0-<5% (reference group)
Number of subjects: 2964

Group type: EXPERIMENTAL
Intervention: Weight gain >5%
Number of subjects: 2964
Study: 27320184

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) prevalence in participants with prior CVD
Number of subjects: 9340

Group type: EXPERIMENTAL
Intervention: Geographical prevalence of CKD
Number of subjects: 9340

Group type: EXPERIMENTAL
Intervention: Factors associated with increased CKD prevalence
Number of subjects: 9340

Group type: EXPERIMENTAL
Intervention: Factors associated with decreased CKD prevalence
Number of subjects: 9340
Study: 23804562

Group type: EXPERIMENTAL
Intervention: Diet plus physical activity (D-PA)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Diet alone (DO)
Number of subjects: 116
Study: 22425411

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Drug Counseling (DC)
Number of subjects: 56
Study: 20074324

Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resurfacing Arthroplasty
Number of subjects: 0
Study: 18751444

Group type: EXPERIMENTAL
Intervention: Paclitaxel (PTX) 80 mg/m2 weekly
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 12.5 mg/m2 every two weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of PTX and PLD
Number of subjects: 30
Study: 15721116

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) implantation
Number of subjects: 137
Study: 12873918

Group type: EXPERIMENTAL
Intervention: 1 micro g/kg IV fentanyl 10 min before discontinuation of anesthetic
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 32